Oruka Therapeutics insider Form 3: Sandler holds 213K shares plus options
Rhea-AI Filing Summary
On 07/01/2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 3 reporting the initial beneficial ownership of its newly appointed Chief Operating Officer, Laura Lee Sandler.
- Direct ownership: 213,084 shares of common stock.
- Derivative securities: • Warrant covering 99,996 shares at an exercise price of $7.80, expiring 07/14/2034. Vesting schedule: 25% on 04/03/2025, remaining shares vest monthly over the subsequent three years. • Employee stock option for 137,500 shares at $12.50, expiring 01/21/2035; vests 1/48 monthly beginning 01/01/2025.
- Potential total ownership: 450,580 shares if all derivatives vest and are exercised.
The disclosure signals meaningful insider alignment through equity ownership and a performance-linked vesting structure. No other transactions or financial metrics were included in this filing.
Positive
- Significant direct insider ownership of 213,084 shares signals alignment with shareholder interests.
- Long-term, performance-linked vesting of options and warrants may incentivize sustained operational execution.
Negative
- Potential dilution of up to 237,496 shares if all options and warrants are exercised.
Insights
TL;DR: Form 3 shows COO holds 213k shares plus 238k options/warrants, indicating strong insider alignment; limited immediate market impact.
This Form 3 establishes Laura Sandler’s baseline ownership in Oruka Therapeutics. A direct stake of 213,084 shares—supplemented by 99,996 warrant shares at $7.80 and 137,500 option shares at $12.50—creates a potential 450,580-share position. The staggered vesting schedules (25% cliff and monthly installments) are designed to retain the executive through 2035 and tie compensation to long-term share performance. From a governance standpoint, the size of the holding is material for a COO of a small-cap biotech and may reassure investors about management’s commitment. However, because no open-market purchases occurred and the derivatives are priced above current ownership cost, the near-term dilutive and signaling effects are modest. Overall impact is neutral to slightly positive.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrant (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This warrant represents a right to purchase 99,996 shares of the Issuer's common stock, one quarter of which will vest on April 3, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
